Find a Tender
planned
Official procurement procedure
Supply of Bluetongue Serotype 3 (BTV-3) Vaccine
Vaccines for veterinary medicine
UK
Published value
£1
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Defra Network eTendering Portal: "Supply of Bluetongue Serotype 3 (BTV-3) Vaccine". Published status: planned. Published value: £1. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Defra Network eTendering Portal | Scope & Categories | Not published | Submission Window | planned No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £1 |
Bidder Intelligence · Authority Profile: Defra Network eTendering Portal
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Defra Network eTendering Portal. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
1.5Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 83 active published awards; 79 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityDefra Network eTendering Portal | Procedure methodNot published | Procurement categoryNot published |
Statusplanned | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published10 May 2024, 14:11 BST | Last source update10 May 2024, 14:11 BST | Recurring procurementNot published |
ClassificationVaccines for veterinary medicine | ||
Delivery area UK | ||
OCIDocds-h6vhtk-0458c0 | ||
What is being bought
The Authority is seeking to identify existing and potential suppliers of bluetongue serotype 3 (BTV-3) vaccine who have product currently under development . We are keen to understand the timelines for applications to the Veterinary Medicines Directorate (VMD) for a marketing authorisation or for emergency use consideration under Schedule 4 of the Veterinary Medicine Regulations 2013, as well as for production timescales for any product to be made available to the UK market. <br/><br/>The Authority is specifically interested in:<br/>- the types of inactivated or novel (e.g. RNA) BTV-3 vaccine being developed.<br/>- the efficacy and period (onset and duration) of immunity they might offer.<br/>- which species they are being developed for<br/>- available safety data in the target species<br/>- the proposed number of doses in the vaccination schedule, <br/>- storage conditions<br/>- readiness to submit the necessary information to the Veterinary Medicines Directorate<br/>- the extent to which the UK livestock sector could be supplied with such product in 2024 or 2025 <br/>- any information that might be provided about potential costs; any expectations around the vaccines being manufactured under the conditions of Good Manufacturing Practice (GMP). <br/><br/>The Authority will not be considering live bluetongue vaccines. <br/><br/>The Authority is seeking this information to inform decisions around guarantees of supply to the UK market. An estimated total value is therefore not provided at this stage.
What changed
From the official release history
- Published value updated to £1
10 May 2024, 14:11 BST - Status changed to planned
10 May 2024, 14:11 BST - Official notice release published
10 May 2024, 14:11 BST - Buyer information updated
10 May 2024, 14:11 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedplannedPublished valueNot publishedThe Authority is exploring the status of BTV-3 vaccine products that have the potential to be available for use in 2024 or 2025 (either as an authorised product or emergency use under Schedule 4) to help to inform our control strategy for bluetongue and consideration as to whether government intervention is required to facilitate access to the UK livestock sector of any product that may become available. <br/><br/>BTV-3 was identified in northern Europe in September 2023 and the UK had its first cases of BTV-3 in November 2023, most likely from plumes of infected midges blown over from the continent. While there is no evidence of circulation currently, we expect a continued threat of incursion as weather conditions become more favourable to vector activity and virus reproduction. It is widely accepted that access to vaccine will be an important tool to protect the health and welfare of susceptible species and for livestock keepers for whom trade in live animals is important. <br/><br/>The Authority is aware that other serotypes of BTV are circulating in Northern Europe, particularly BTV-4 and BTV-8 and so information on any multivalent BTV-3 vaccines that also contain other serotypes would be of interest. <br/><br/>The Authority is interested in:<br/>- the details of any suitable products currently under development <br/>- the extent of developments<br/>- safety and efficacy testing, timelines for submitting applications for marketing authorisation to the VMD.<br/>- the type of technology used to develop the vaccine, production capacity (current and forecast)<br/>- whether the specific vaccine is authorised elsewhere in the world or based on an already authorised BTV vaccine. <br/>- whether products under development will be monovalent or multivalent and which serotypes would be included in multivalent products. <br/><br/>We are also interested to understand the likely wholesale and retail costs of any product likely to be available. Additional information: This Prior Information Notice (PIN) is not a call for competition. It should be noted that this PIN invites individuals and organisations to express an interest only, and although it is not part of a formal pre-qualification process it may be used to inform discussions with vaccine suppliers. <br/><br/>You will need to express your interest in any potential future tender opportunity once/if a contract notice is published in Find a Tender and on Contract Finder. It should be noted that this PIN invites individuals and organisations to express an interest only. Those wishing to provide information requested here should contact Louise Moizer (louise.moizer@defra.gov.uk), by the end of May to inform our strategy development.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
10 May 2024, 14:11 BST
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
Defra Network eTendering Portal
Contracting authority GB-FTS-99321Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published